Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment
DOI:
https://doi.org/10.15392/2319-0612.2022.2047Keywords:
Thyroid Neoplasms, Quality of Life, Iodine RadioisotopesAbstract
Radioiodine therapy (RIT) is a complementary treatment to total thyroidectomy in differentiated thyroid cancer (DTC) patients. High levels of thyroid-stimulating hormone (TSH) are usually required in clinical practice to increase RIT efficacy. Suspension of levothyroxine hormone for weeks is usually necessary, greatly impacting patients' quality of life. Patients with DTC of low or intermediate-risk were divided into two groups - one where levothyroxine was suspended for 4-5 weeks and a TSH ≥ 30 mUI/L was required for radioiodine administration (group 1), and another where levothyroxine was suspended for two weeks only (group 2). The RIT efficacy was compared between the groups. The absorbed dose in the cervical region after 24 hours was also calculated and correlated with TSH. The quality of life was also accessed with the EORTC questionnaire. Thirty-one patients were included in this study (14 in group 1 and 17 in group 2), with a mean age of 45.7 ± 10.6 years and 29 (93.5%) females. The mean TSH level for group 1 was 67.0 ± 35.6 UI/ml, and for group 2 was 31.3 ± 29.4 UI/ml. After six months, the successful RIT frequency was 66.6% for group 1 and 73.3% for group 2. Patients from group 2 showed better quality of life. TSH level ≥ 30 mUI/L is not critical for the success of RIT in patients with low or intermediate risk DTC. A two-week suspension of thyroid hormone appears to meet similar RIT needs, providing a better quality of life.
Downloads
References
Becker D V., Sawin CT. Radioiodine and thyroid disease: The beginning. Semin Nucl Med 1996; 26: 155–164. DOI: https://doi.org/10.1016/S0001-2998(96)80020-1
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1–133. DOI: https://doi.org/10.1089/thy.2015.0020
Carvalho DP, Ferreira ACF. The importance of sodium/iodide symporter (NIS) for thyroid cancer management. Arq Bras Endocrinol Metabol 2007; 51: 672–682. DOI: https://doi.org/10.1590/S0004-27302007000500004
Kogai T, Brent G a. The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 2012; 135: 355–370. DOI: https://doi.org/10.1016/j.pharmthera.2012.06.007
Harun-Or-Rashid M, Asai M, Sun X, et al. Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice. Thyroid Res 2010; 3: 1–6. DOI: https://doi.org/10.1186/1756-6614-3-3
Edmonds CJ, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977; 50: 799–807. DOI: https://doi.org/10.1259/0007-1285-50-599-799
Mernagh P, Campbell S, Dietein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. Eur J Endocrinol 2006; 155: 405–414. DOI: https://doi.org/10.1530/eje.1.02223
Mernagh P, Suebwongpat A, Silverberg J, et al. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective. Value Heal 2010; 13: 180–187. DOI: https://doi.org/10.1111/j.1524-4733.2009.00650.x
Vallejo JA, Muros MA. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals. Rev Esp Med Nucl Imagen Mol 2017; 36: 362–370. DOI: https://doi.org/10.1016/j.remnie.2017.09.001
Van Velsen EFS, Massolt ET, Heersema H, et al. Longitudinal analysis of quality of life in patients treated for differentiated thyroid cancer. Eur J Endocrinol 2019; 181: 671–679. DOI: https://doi.org/10.1530/EJE-19-0550
Ahn J, Jeon MJ, Song E, et al. Quality of life in patients with papillary thyroid microcarcinoma according to treatment: Total thyroidectomy with or without radioactive iodine ablation. Endocrinol Metab 2020; 35: 115–121. DOI: https://doi.org/10.3803/EnM.2020.35.1.115
Mínguez P, Flux G, Genollá J, et al. Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer. Med Phys 2016; 43: 5279–5287. DOI: https://doi.org/10.1118/1.4961742
Benjamin RS, Amro A, El-Desouki MI. Measurement of iodine-123 thyroid uptake using a gamma camera with LEAP collimator. J Nucl Med Technol. 1999 Sep;27(3):215-9.
Erçikti N, Acer N, Apaydi N, et al. Which Method is Gold Standard for Determination of Thyroid Volume? Int J Morphol 2017; 35: 452–458. DOI: https://doi.org/10.4067/S0717-95022017000200011
Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000; 41: 149–160.
Franceschini J, Jardim JR, Fernandes ALG, et al. Reprodutibilidade da versão em português do Brasil do European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire em conjunto com seu módulo específico para câncer de pulmão. J Bras Pneumol 2010; 36: 595–602. DOI: https://doi.org/10.1590/S1806-37132010000500011
EORTC Data Center. EORTC QLQ-C30 Scoring Manual, https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (2001, accessed 7 March 2022).
González P, Jaimovich R, Araya V, Massardo T, Carmona A. Endogenous thyroid-stimulating hormone and radioactive iodine uptake in normal subjects. Clin Nucl Med. 2012 Jun;37(6):584-6. DOI: https://doi.org/10.1097/RLU.0b013e3182478d75
Vrachimis A, Riemann B, Mäder U, et al. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mol Imaging 2016; 43: 224–231. DOI: https://doi.org/10.1007/s00259-015-3223-2
Hasbek Z, Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? Malecular Imaging Radionucl Ther 2016; 25: 79–84. DOI: https://doi.org/10.4274/mirt.88598
Xiao J, Yun C, Cao J, et al. A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients. Sci Rep 2021; 11: 1–8. DOI: https://doi.org/10.1038/s41598-020-80015-8
Ha S, Oh SW, Kim YK, et al. Clinical outcome of remnant thyroid ablation with low dose radioiodine in Korean patients with low to intermediate-risk thyroid cancer. J Korean Med Sci 2015; 30: 876–881. DOI: https://doi.org/10.3346/jkms.2015.30.7.876
Verburg FA, Mäder U, Reiners C, et al. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical131I therapy in both high- And low-risk patients. J Clin Endocrinol Metab 2014; 99: 4487–4496. DOI: https://doi.org/10.1210/jc.2014-1631
Ravera S, Reyna-Neyra A, Ferrandino G, et al. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol 2017; 79: 261–289. DOI: https://doi.org/10.1146/annurev-physiol-022516-034125
Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214. DOI: https://doi.org/10.1089/thy.2009.0110
Piccardo A, Puntoni M, Ferrarazzo G, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? Eur J Nucl Med Mol Imaging 2018; 45: 1218–1223. DOI: https://doi.org/10.1007/s00259-018-3955-x
Tagay S, Herpertz S, Langkafel M, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755–763. DOI: https://doi.org/10.1530/eje.1.02047
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
